Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial ...

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's Full Year and Q4 2024 results. [Operator Instructions].

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices are usually driven by a company’s financial performance over the long term ...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

Investing in Canadian growth stocks such as Cipher and Lumine can help you generate outsized gains in 2025 and beyond.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS) ...

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology.